Ataluren is indicated for:
Population group: both men and women, only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Ataluren is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older.
The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Ataluren is contraindicated in the following cases: